Astria Therapeutics, Inc.
ATXS
$7.49
-$0.04-0.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.95% | -31.54% | -4.45% | -1.50% | -21.30% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.30% | 32.95% | 13.10% | 8.74% | -15.79% |
| Change in Net Operating Assets | -102.41% | -157.15% | 208.35% | -199.84% | 490.13% |
| Cash from Operations | -6.00% | -95.93% | 37.92% | -66.55% | 12.06% |
| Capital Expenditure | -- | -- | 100.00% | 93.44% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 104.95% | 868.98% | -159.87% | 109.16% | 46.29% |
| Cash from Investing | 102.89% | 868.98% | -160.07% | 109.09% | 46.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 16,177.66% | -99.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | 16,177.66% | -99.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 503.57% | 74.22% | -225.49% | 92.36% | -2,310.46% |